Niagen Bioscience (stock code: NAGE) recently announced its financial results for fiscal year 2025, delivering an impressive performance.

On October 7: Vaxcyte (PCVX.O) shares fell 0.3% in premarket trading on Wednesday to $66.50, after the company completed a $1.1 billion financing round. On Tuesday night, PCVX announced the pricing (link) of approximately 7.8 million shares of common stock and pre-funded warrants at $64 per share, raising $500 million in total; simultaneously, the company launched a public offering of $500 million of convertible senior notes with a coupon rate of 1.5%, maturing on October 15, 2032. The conversion price of the convertible notes is $89.60, representing a 40% premium over the equity offering price. On Monday, PCVX shares surged around 31% after the company announced that its pneumococcal vaccine VAX-31 met all primary endpoints in late-stage clinical trials (link), generating an immune response at least comparable to that of Pfizer’s Prevnar 20 (PFE.N) and Merck’s Capvaxive (MRK.N). On Tuesday, following the launch of the public offering (link), the stock closed down nearly 10% at $66.70. PCVX plans to use the net proceeds from this offering to fund clinical development of the VAX-31 adult and pediatric programs, including the ongoing adult Phase III clinical trial of VAX-31. Jefferies, Leerink, BofA, Evercore, Goldman Sachs, and Guggenheim are joint book-running managers for the equity offering; Jefferies, Leerink, BofA, Goldman Sachs, and Evercore act as lead managers for the convertible notes transaction. As of Tuesday’s close, PCVX shares are up about 45% year-to-date.

October 7 - Cantor Fitzgerald has upgraded its rating on health insurance company Humana (HUM.N) from "Neutral" to "Overweight" and raised the target price from $300 to $460. The brokerage increased its 2027 EPS estimate from $15.86 to $17.96 and its 2028 estimate from $25.38 to $28.27, citing increased confidence in HUM's margin performance and quality rating recovery within the Medicare Advantage plan. Cantor expects this week’s upcoming Medicare quality ratings to be positive, and better scores would help HUM secure higher government bonuses in 2028. The brokerage stated that pricing strategies, benefits adjustments, and measures to control medical costs are expected to significantly improve Medicare margins in 2027. It believes that confirmation of HUM's 2027 performance forecast and 2027 membership in line with expectations will be the next potential catalyst following the quality ratings release. Cantor noted that HUM currently trades at 9.9 times management’s midpoint 2028 earnings forecast, compared to a historical average P/E of about 18x. (For the convenience of non-English speakers, Reuters may provide automated translations of its report into multiple languages. Due to possible errors or lack of appropriate context, Reuters does not guarantee the accuracy of translated text and provides automated translations solely for reader convenience. Reuters assumes no responsibility for any damage or loss resulting from the use of automated translation functions.)

06:41 AM EDT, 10/07/2026 (MT Newswires) -- RWE Chief Executive Markus Krebber said any involvement by the German utility in Uniper would be limited after RWE and KKR (KKR) submitted a joint non-binding bid for the state-owned energy company, Bloomberg reported Wednesday. RWE is not targeting a takeover, given its significant position in Germany's energy market, Krebber said in an interview with Bloomberg. RWE did not immediately respond to MT Newswires' request for comment. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)